Jnana Therapeutics Launches With $50 Million Series A Financing to Target the Cell’s Metabolic Gates

Jnana Therapeutics Inc. today announced its launch with a $50 million Series A financing. The company is building the first drug discovery platform dedicated to targeting the solute carrier (SLC) family of transporters, the cell’s metabolic gates. Jnana’s proprietary small molecule platform allows the company to address therapeutic targets rapidly and comprehensively across the SLC transporter family.

Read More